KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) EPS (Basic) (2016 - 2025)

Resmed (RMD) has disclosed EPS (Basic) for 17 consecutive years, with $2.7 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 14.89% year-over-year to $2.7, compared with a TTM value of $10.16 through Dec 2025, up 19.53%, and an annual FY2025 reading of $9.55, up 37.61% over the prior year.
  • EPS (Basic) was $2.7 for Q4 2025 at Resmed, up from $2.38 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.7 in Q4 2025 and bottomed at -$0.54 in Q1 2021.
  • Average EPS (Basic) over 5 years is $1.69, with a median of $1.55 recorded in 2023.
  • The sharpest move saw EPS (Basic) plummeted 147.79% in 2021, then skyrocketed 325.93% in 2022.
  • Year by year, EPS (Basic) stood at $1.38 in 2021, then rose by 10.87% to $1.53 in 2022, then fell by 7.19% to $1.42 in 2023, then skyrocketed by 65.49% to $2.35 in 2024, then rose by 14.89% to $2.7 in 2025.
  • Business Quant data shows EPS (Basic) for RMD at $2.7 in Q4 2025, $2.38 in Q3 2025, and $2.59 in Q2 2025.